Summary

Hsp104 के शोधन, एक प्रोटीन Disaggregase

Published: September 30, 2011
doi:

Summary

यहाँ, हम अत्यधिक सक्रिय Hsp104, hexameric + खमीर, जो जोड़ों एटीपी प्रोटीन disaggregation hydrolysis से एएए प्रोटीन की शुद्धि के लिए एक प्रोटोकॉल का वर्णन. इस योजना के कारनामे His6 टैग से आत्मीयता शुद्धि के लिए का निर्माण<em> ई. कोलाई</em> आयनों मुद्रा क्रोमैटोग्राफी, TEV protease के साथ His6 टैग हटाने, और आकार अपवर्जन क्रोमैटोग्राफी द्वारा पीछा किया.

Abstract

Hsp104 is a hexameric AAA+ protein1 from yeast, which couples ATP hydrolysis to protein disaggregation2-10 (Fig. 1). This activity imparts two key selective advantages. First, renaturation of disordered aggregates by Hsp104 empowers yeast survival after various protein-misfolding stresses, including heat shock3,5,11,12. Second, remodeling of cross-beta amyloid fibrils by Hsp104 enables yeast to exploit myriad prions (infectious amyloids) as a reservoir of beneficial and heritable phenotypic variation13-22. Remarkably, Hsp104 directly remodels preamyloid oligomers and amyloid fibrils, including those comprised of the yeast prion proteins Sup35 and Ure223-30. This amyloid-remodeling functionality is a specialized facet of yeast Hsp104. The E. coli orthologue, ClpB, fails to remodel preamyloid oligomers or amyloid fibrils26,31,32.

Hsp104 orthologues are found in all kingdoms of life except, perplexingly, animals. Indeed, whether animal cells possess any enzymatic system that couples protein disaggregation to renaturation (rather than degradation) remains unknown33-35. Thus, we and others have proposed that Hsp104 might be developed as a therapeutic agent for various neurodegenerative diseases connected with the misfolding of specific proteins into toxic preamyloid oligomers and amyloid fibrils4,7,23,36-38. There are no treatments that directly target the aggregated species associated with these diseases. Yet, Hsp104 dissolves toxic oligomers and amyloid fibrils composed of alpha-synuclein, which are connected with Parkinson’s Disease23 as well as amyloid forms of PrP39. Importantly, Hsp104 reduces protein aggregation and ameliorates neurodegeneration in rodent models of Parkinson’s Disease23 and Huntington’s disease38. Ideally, to optimize therapy and minimize side effects, Hsp104 would be engineered and potentiated to selectively remodel specific aggregates central to the disease in question4,7. However, the limited structural and mechanistic understanding of how Hsp104 disaggregates such a diverse repertoire of aggregated structures and unrelated proteins frustrates these endeavors30,40-42.

To understand the structure and mechanism of Hsp104, it is essential to study the pure protein and reconstitute its disaggregase activity with minimal components. Hsp104 is a 102kDa protein with a pI of ~5.3, which hexamerizes in the presence of ADP or ATP, or at high protein concentrations in the absence of nucleotide43-46. Here, we describe an optimized protocol for the purification of highly active, stable Hsp104 from E. coli. The use of E. coli allows simplified large-scale production and our method can be performed quickly and reliably for numerous Hsp104 variants. Our protocol increases Hsp104 purity and simplifies His6-tag removal compared to a previous purification method from E. coli47. Moreover, our protocol is more facile and convenient than two more recent protocols26,48.

Protocol

1. Hsp104 की अभिव्यक्ति प्लाज्मिड ई. में शुद्धि के लिए नियोजित कोलाई, pPROEX HTB-Hsp104 Hsp104 TRC 26 प्रमोटर के inducible नियंत्रण के तहत खुले पढ़ने फ्रेम शामिल हैं . प्लाज्मिड एन टर्मिनल उनकी 6 टैग कि TEV protease दरा?…

Discussion

समयरेखा: हम अधिक से अधिक Hsp104 गतिविधि के लिए सुझाव है कि पूरे शुद्धि योजना के रूप में तेजी से संभव के रूप में पूरा किया जाना. हालांकि, शुद्धि चरणों की संख्या एक मांग अनुसूची है कि हमेशा व्यावहारिक नहीं ह?…

Disclosures

The authors have nothing to disclose.

Acknowledgements

यह काम (5T32GM008275 22) NIH और एक अमेरिकन हार्ट एसोसिएशन predoctoral फेलोशिप (ईएएस के लिए) से एक अनुदान द्वारा समर्थित किया गया, रसायन विज्ञान जीवविज्ञान (2T32GM071339 06A1) NIH (मेड करने के लिए) से इंटरफ़ेस फैलोशिप, और से अनुदान (1DP2OD002177-01 और NS067354 – 0,110) एनआईएच, एलिसन मेडिकल फाउंडेशन, और बिल और मेलिंडा गेट्स फाउंडेशन (जे एस के लिए).

Materials

Name of the reagent Company Catalogue number
BL21-CodonPlus-RIL Competent Cells Stratagene, Agilent Technologies 230255
2XYT broth USB 75864
Complete, mini, EDTA-free protease inhibitor tablets Roche 1836170
Pepstatin A Sigma P4265
Ni-Sepharose 6 Fast Flow GE Healthcare 17-5318-02
Amicon Ultra-15 centrifugal filter units (MWCO 30,000) Millipore UFC903008
Resource Q – 6ml column GE Healthcare 17-1179-01
proTEV Protease Promega V6052
AcTEV Protease Invitrogen 12575015
Superose 6 10/300 GL GE Healthcare 17-5172-01
Hsp40 Assay Designs SPP-400
Hsp72 Assay Designs ADI-NSP-555

References

  1. Erzberger, J. P., Berger, J. M. Evolutionary relationships and structural mechanisms of AAA+ proteins. Annu Rev Biophys Biomol Struct. 35, 93-114 (2006).
  2. Glover, J. R., Lindquist, S. Hsp104, Hsp70, and Hsp40: A Novel Chaperone System that Rescues Previously Aggregated Proteins. Cell. 94, 73-82 (1998).
  3. Parsell, D. A., Kowal, A. S., Singer, M. A., Lindquist, S. Protein disaggregation mediated by heat-shock protein Hsp104. Nature. 372, 475-478 (1994).
  4. Vashist, S., Cushman, M., Shorter, J. Applying Hsp104 to protein-misfolding disorders. Biochem Cell Biol. 88, 1-13 (2010).
  5. Parsell, D. A., Sanchez, Y., Stitzel, J. D., Lindquist, S. Hsp104 is a highly conserved protein with two essential nucleotide-binding sites. Nature. 353, 270-273 (1991).
  6. Doyle, S. M., Wickner, S. Hsp104 and ClpB: protein disaggregating machines. Trends Biochem Sci. 34, 40-48 (2009).
  7. Shorter, J. Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals. 16, 63-74 (2008).
  8. Glover, J. R., Lum, R. Remodeling of protein aggregates by Hsp104. Protein Pept Lett. 16, 587-597 (2009).
  9. Mogk, A., Haslberger, T., Tessarz, P., Bukau, B. Common and specific mechanisms of AAA+ proteins involved in protein quality control. Biochem Soc Trans. 36, 120-125 (2008).
  10. Grimminger-Marquardt, V., Lashuel, H. A. Structure and function of the molecular chaperone Hsp104 from yeast. Biopolymers. 93, 252-276 (2010).
  11. Sanchez, Y., Lindquist, S. L. HSP104 required for induced thermotolerance. Science. 248, 1112-1115 (1990).
  12. Sanchez, Y., Taulien, J., Borkovich, K. A., Lindquist, S. Hsp104 is required for tolerance to many forms of stress. Embo J. 11, 2357-2364 (1992).
  13. Alberti, S., Halfmann, R., King, O., Kapila, A., Lindquist, S. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell. 137, 146-158 (2009).
  14. Halfmann, R., Alberti, S., Lindquist, S. Prions, protein homeostasis, and phenotypic diversity. Trends Cell Biol. 20, 125-1233 (2010).
  15. Shorter, J., Lindquist, S. Prions as adaptive conduits of memory and inheritance. Nat Rev Genet. 6, 435-450 (2005).
  16. True, H. L., Berlin, I., Lindquist, S. L. Epigenetic regulation of translation reveals hidden genetic variation to produce complex traits. Nature. 431, 184-187 (2004).
  17. True, H. L., Lindquist, S. L. A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature. 407, 477-483 (2000).
  18. Tyedmers, J., Madariaga, M. L., Lindquist, S. Prion switching in response to environmental stress. PLoS Biol. 6, e294-e294 (2008).
  19. Chernoff, Y. O., Lindquist, S. L., Ono, B., Inge-Vechtomov, S. G., Liebman, S. W. Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [psi+]. Science. 268, 880-884 (1995).
  20. Halfmann, R., Lindquist, S. Epigenetics in the extreme: prions and the inheritance of environmentally acquired traits. Science. 330, 629-632 (2010).
  21. Satpute-Krishnan, P., Langseth, S. X., Serio, T. R. Hsp104-dependent remodeling of prion complexes mediates protein-only inheritance. PLoS Biol. 5, e24-e24 (2007).
  22. Sweeny, E. A., Shorter, J. Prion proteostasis: Hsp104 meets its supporting cast. Prion. 2, 135-140 (2008).
  23. Lo Bianco, C. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest. 118, 3087-3097 (2008).
  24. Narayanan, S., Walter, S., Reif, B. Yeast prion-protein, sup35, fibril formation proceeds by addition and substraction of oligomers. Chembiochem. 7, 757-765 (2006).
  25. Savistchenko, J., Krzewska, J., Fay, N., Melki, R. Molecular chaperones and the assembly of the prion Ure2p in vitro. J Biol Chem. 283, 15732-15739 (2008).
  26. Shorter, J., Lindquist, S. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science. 304, 1793-1797 (2004).
  27. Shorter, J., Lindquist, S. Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell. 23, 425-438 (2006).
  28. Shorter, J., Lindquist, S. Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions. Embo J. 27, 2712-2724 (2008).
  29. Doyle, S. M. Asymmetric deceleration of ClpB or Hsp104 ATPase activity unleashes protein-remodeling activity. Nat Struct Mol Biol. 14, 114-122 (2007).
  30. Wendler, P. Atypical AAA+ subunit packing creates an expanded cavity for disaggregation by the protein-remodeling factor Hsp104. Cell. 131, 1366-1377 (2007).
  31. Hinault, M. P. Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones. J Biol Chem. 285, 38173-38182 (2010).
  32. Tipton, K. A., Verges, K. J., Weissman, J. S. In vivo monitoring of the prion replication cycle reveals a critical role for Sis1 in delivering substrates to Hsp104. Mol Cell. 32, 584-591 (2008).
  33. Bieschke, J., Cohen, E., Murray, A., Dillin, A., Kelly, J. W. A kinetic assessment of the C. elegans amyloid disaggregation activity enables uncoupling of disassembly and proteolysis. Protein Sci1. 8, 2231-2241 (2009).
  34. Cohen, E., Bieschke, J., Perciavalle, R. M., Kelly, J. W., Dillin, A. Opposing activities protect against age-onset proteotoxicity. Science. 313, 1604-1610 (2006).
  35. Cohen, E. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell. 139, 1157-1169 (2009).
  36. Cushman, M., Johnson, B. S., King, O. D., Gitler, A. D., Shorter, J. Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci. 23, 1191-11201 (2010).
  37. Carmichael, J. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington’s disease. Proc Natl Acad Sci. 97, 9701-9705 (2000).
  38. Vacher, C., Garcia-Oroz, L., Rubinsztein, D. C. Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington’s disease. Hum Mol Genet. 14, 3425-3433 (2005).
  39. Liu, Y. H. Heat Shock Protein 104 Inhibited the Fibrillization of Prion Peptide 106-126 and Disassembled Prion peptide 106-126 Fibrils in vitro. Int J Biochem Cell Biol. , (2011).
  40. Wendler, P., Saibil, H. R. Cryo electron microscopy structures of Hsp100 proteins: crowbars in or out. Biochem Cell Biol. 88, 89-96 (2010).
  41. Wendler, P. Motor mechanism for protein threading through Hsp104. Mol Cell. 34, 81-92 (2009).
  42. Lee, S., Sielaff, B., Lee, J., Tsai, F. T. CryoEM structure of Hsp104 and its mechanistic implication for protein disaggregation. Proc Natl Acad Sci. 107, 8135-8140 (2010).
  43. Parsell, D. A., Kowal, A. S., Lindquist, S. Saccharomyces cerevisiae Hsp104 protein. Purification and characterization of ATP-induced structural changes. J Biol Chem. 269, 4480-4487 (1994).
  44. Schirmer, E. C., Queitsch, C., Kowal, A. S., Parsell, D. A., Lindquist, S. The ATPase activity of Hsp104, effects of environmental conditions and mutations. J Biol Chem. 273, 15546-15552 (1998).
  45. Schirmer, E. C., Ware, D. M., Queitsch, C., Kowal, A. S., Lindquist, S. L. Subunit interactions influence the biochemical and biological properties of Hsp104. Proc Natl Acad Sci. 98, 914-919 (2001).
  46. Hattendorf, D. A., Lindquist, S. L. Cooperative kinetics of both Hsp104 ATPase domains and interdomain communication revealed by AAA sensor-1 mutants. EMBO J. 21, 12-21 (2002).
  47. Schirmer, E. C., Lindquist, S. Purification and properties of Hsp104 from yeast. Methods Enzymol. 290, 430-444 (1998).
  48. Hattendorf, D. A., Lindquist, S. L. Analysis of the AAA sensor-2 motif in the C-terminal ATPase domain of Hsp104 with a site-specific fluorescent probe of nucleotide binding. Proc Natl Acad Sci. 99, 2732-2737 (2002).
  49. Lum, R., Niggemann, M., Glover, J. R. Peptide and protein binding in the axial channel of Hsp104. Insights into the mechanism of protein unfolding. J Biol Chem. 283, 30139-30150 (2008).
  50. Lum, R., Tkach, J. M., Vierling, E., Glover, J. R. Evidence for an unfolding/threading mechanism for protein disaggregation by Saccharomyces cerevisiae Hsp104. J Biol Chem. 279, 29139-29146 (2004).
  51. Tessarz, P., Mogk, A., Bukau, B. Substrate threading through the central pore of the Hsp104 chaperone as a common mechanism for protein disaggregation and prion propagation. Mol Microbiol. 68, 87-97 (2008).
  52. Weibezahn, J. Thermotolerance requires refolding of aggregated proteins by substrate translocation through the central pore of ClpB. Cell. 119, 653-665 (2004).
check_url/3190?article_type=t

Play Video

Cite This Article
Sweeny, E. A., DeSantis, M. E., Shorter, J. Purification of Hsp104, a Protein Disaggregase. J. Vis. Exp. (55), e3190, doi:10.3791/3190 (2011).

View Video